Pulmonary Vasodilators. Part 2
Vasodilatadores pulmonares Parte 2
Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.
Show authors biography
Pulmonary vasodilators are drugs which are currently used in the management of patients with pulmonary arterial hypertension. They have been introduced over the last few years, and many of them are already available in Colombia. However, the advent of these therapies demands a deeper knowledge of their actions, potential interactions, mechanisms of action, and adverse effects, as well as the benefits which have been demostrated in several clinical trials, so that the physician is able to make the best choice for each individual suffering from this disease according to group, comorbidities, and functional class, as well as to teach both the physician and the patient to recognize their potential adverse events.
Article visits 563 | PDF visits 1205
Downloads
- Warwick G, Thomas PS, Yates DH. Biomarkers in pulmonary hypertension. Eur Respir J. 2008;32:503-512.
- Giaid A, Yanagsisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hipertensión. N Engl J Med. 1993;328:1732-1739.
- Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by the vascular endothelial cells. Nature 1988;332:411-15.
- Hoger G, Schwarz A, Fagan KA, et al. Pulmonary Fibrosis and chronic lung inflammation in ET-1 Trasgenic mice. Am J Respir Cell Mol Biol 2000;23:19-26.
- Channick R, Sitbon O, Barst RJ, Manes A, Rubin LJ. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:62S-67S.
- Dupuis J. Endothelin/receptor antagonists in pulmonary hypertension. Lancet. 2001;358:1113-1114.
- Rubens C, Ewert R, Halank M, et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest. 2001;120:1562-1569.
- Barst RJ. A review of pulmonary arterial hypertension: role of ambrisentan. Vasc Health Risk Manag. 2007;3:11-22.
- Mano Y, Usui T, Kamimura H. Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance associated protein 2. Biopharm Drug Dispos. 2007;28:13-18.
- Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebocontrolled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117:3010-9.
- Oudiz RJ, Galié N, Olschewski H, et al. Am Coll Cardiol. 2009;54:1971-81.
- Casserly B, Klinger JR. Ambrisentan for the treatment of pulmonary arterial hypertension. Drug Design, Development and Therapy. 2008;2:265-280.
- Dufton C, Gerber M, Yin O, et al. No clinically relevant pharmacokinetic interaction between ambrisentan and sildenafil. Chest. 2006;130:254S.
- Volibris®. Monografía del producto. 2008.
- Tacleer® Monografía del producto. 2004.
- Jasmin J, Lucas M, Cernacek P, Dupuis J. Effectiveness of a nonselective ETA/B and a selective ETA antagonist in rats with monocrotalineinduced pulmonary hypertension. Circulation. 2001;103:314-318.
- Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896-903.
- Channick R, Sunomeau G, Sitbon O, et al. Effects of the dual endothelinreceptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo controlled study. Lancet 2001;358:1119-23.
- Sitbon O, Badesch DB, Channick RN, et al. Effects of the dual endothelin antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003;124:247-54.
- D’Alto M, Vizza CD, Romeo E, et al. Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect. Heart 2007;93:621-625.
- Galiè N, Beghetti M, Gatzoulis MA; et al. For the Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) investigators. Bosentan therapy in patients with eisenmenger syndrome a multicenter, double-blind, randomized, placebo- controlled study. Circulation. 2006;114:48-54.
- Hoeper MM, Kramm T, Wilkens H, Schulze C. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. CHEST 2005;128:2363-2367.
- Galie N, Rubin LJ, Hoeper MM et al. Treatment of patients with
- mildly symptomatic pulmonary arterial hypertension with bosentan
- (EARLY study): a double-blind, randomised controlled trial. Lancet
- ;371:2093-100.
- Galié N, Corris PA, Frost A, et al. Updated treatment algorthm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62:D60-72.
- Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369:809-18.
Information
Journal history
Keywords
QR code
Funding
Directories and indexes
